The molecular mechanism of Ligusticum wallichii for improving idiopathic pulmonary fibrosis: A network pharmacology and molecular docking study

Studying the efficacy of JBOL volatile components in idiopathic pulmonary fibrosis (IPF) using GC-MS and network pharmacology

Jin Bei oral liquid (JBOL) is a Chinese medicinal preparation for the treatment of idiopathic pulmonary fibrosis (IPF), Clinical trials have shown that IPF patients using JBOL have improved their lung function indicators FVC% and DLCO% by approximately 2.10% and 7.74%, suggesting that the agent has a positive effect in slowing disease progression. In this study, the active volatile components of JBOL were systematically identified and analyzed using gas chromatography-mass spectrometry (GC-MS), network pharmacology and molecular docking techniques. It was found that JBOL contains a variety of compounds with antifibrotic potential, which act through multi-target and multi-pathway mechanisms. Network pharmacological analyses revealed multiple targets of JBOL associated with key pathological processes in IPF, and key active ingredients were screened based on degree values (including Sedanolide, Ligustilide, Senkyunolide H, Senkyunolide I, α-Terpineol, and 4-Terpineol). Molecular docking results showed that these compounds have high affinity for target proteins. Finally, suitable quantitative methods were established and methodologically validated for these six compounds, and these methods were used to determine the content of 8 batches of JBOL and analyze the differences in content between batches.The present study provides a scientific basis for the quality control and standardization of its JBOL by identifying and analyzing its active volatile components.

Integrating machine learning and human use experience to identify personalized pharmacotherapy in Traditional Chinese Medicine: a case study on resistant hypertension

OBJECTIVE

To enhance the understanding of identifying personalized pharmacotherapy options in Traditional Chinese Medicine (TCM), and further support the registration of new TCM drugs.

METHODS

Generalized Boosted Models and XGBoost were employed to construct a classification model to identify the bad prognosis factors in resistant hypertension (RH) patients. Furthermore, we used association analysis to explore the rules of "symptom-syndrome" and "symptom-herb" for the major influencing factors, in order to summarize prescription pattern and applicable patients of TCM.

RESULTS

Patients with major adverse cardiac events mostly have complex symptoms of phlegm, stasis, deficiency and fire intermingled with each other, and finally summarized the human experience of using Chinese herbal medicine to precisely intervene in some symptoms of RH patients on the basis of conventional Western medical treatment.

CONCLUSIONS

Machine learning algorithms can make full use of human use experience and evidence to save clinical trial resources and accelerate the development of TCM varieties.

Study on the mechanism of glucose-lowering and sweetening of key sweet aroma compounds in sweet orange

Rising living standards heighten the demand for healthier sugar-reduced foods. This study used Headspace Solid-Phase Microextraction (HS-SPME) and Gas Chromatography-Olfactometry-Mass Spectrometry (GC/O-AT) to analyze volatile components in sweet orange juice, identifying 12 key sweet aroma compounds. Sensory and electronic tongue evaluations indicated that seven sweetness-related odor substances- (E)-citral, (E)-β-farnesene, β-myrcene, tallo-ocimene, nonanal, citronellyl formate, and tallo-ocimene-significantly enhanced the sweetness of a 5 % sucrose solution. In contrast, while nonanol was found to have no sugar-reducing sweetness-enhancing effect. Furthermore, molecular docking analysis was employed to examine the regions, binding energies, and interaction forces between eight sweet and fragrant aroma compounds from sweet orange and the T1R2-T1R3 sweet taste receptor-sucrose ternary system. The average binding energies with the receptor were -3.2 kcal/mol, -1.2 kcal/mol, -3.0 kcal/mol, -1.6 kcal/mol, -5.9 kcal/mol, -5.8 kcal/mol, -3.6 kcal/mol, and -6.0 kcal/mol, respectively. However, it should be noted that binding energy alone is not the sole criterion for judging the sweetening effect. Molecular dynamics (MD) results further demonstrated that the stability of the binding between sucrose and the sweet taste receptor was improved under the influence of (E)-citral, with the interaction between the two relying on hydrogen bonds, water bridges, and hydrophobic forces. This provides a theoretical basis for validating the sweetness-enhancing effects of aroma substances and insights into novel sweetener development.

Evaluation of the Pharmaceutical Activities of Chuanxiong, a Key Medicinal Material in Traditional Chinese Medicine

Szechwan lovage rhizome (SLR, the rhizome of Ligusticum chuanxiong Hort., Chuanxiong in Chinese transliteration) is one Chinese materia medica (CMM) commonly used to activate blood circulation and remove blood stasis. SLR is applicable to most blood stasis syndromes. It has significant clinical efficacy in relation to human diseases of the cardiocerebrovascular system, nervous system, respiratory system, digestive system, urinary system, etc. Apart from China, SLR is also used in Singapore, Malaysia, the European Union, and the United States of America. However, the current chemical markers in pharmacopeia or monography for the quality assessment of SLR are not well characterized or specifically characterized, nor do they fully reflect the medicinal efficacy of SLR, resulting in the quality of SLR not being effectively controlled. CMM can only have medicinal efficacy when they are applied in vivo to an organism. The intensity of their pharmaceutical activities can more directly represent the quality of CMM. Therefore, the chemical constituents and pharmacological actions of SLR are reviewed in this paper. In order to demonstrate the medicinal efficacy of SLR in promoting blood circulation and removing blood stasis, bioassay methods are put forward to evaluate the pharmaceutical activities of SLR to improve hemorheology, hemodynamics, and vascular microcirculation, as well as its anti-platelet aggregation and anticoagulation properties. Through comprehensive analyses of these pharmaceutical properties, the quality and therapeutic value of SLR are ascertained.

Qilongtian ameliorate bleomycin-induced pulmonary fibrosis in mice via inhibiting IL-17 signal pathway

Pulmonary fibrosis (PF) is a special type of pulmonary parenchymal disease, with chronic, progressive, fibrosis, and high mortality. There is a lack of safe, effective, and affordable treatment methods. Qilongtian (QLT) is a traditional Chinese prescription that is composed of Panax notoginseng, Earthworm, and Rhodiola, and shows the remarkable clinical curative effect of PF. However, the mechanism of QLT remains to be clarified. Therefore, we studied the effectivity of QLT in treating Bleomycin (BLM) induced PF mice. 36 C57BL/6 J mice were randomized into the control group, the model group, the low-, medium- and high-dose QLT group, and Pirfenidone group. After establishing a model of pulmonary fibrosis in mice, the control and model groups were infused with a normal saline solution, and the delivery group was infused with QLT. Pulmonary function in the mice from each group was detected. Pulmonary tissue morphologies and collagen deposition were stained by HE and Masson. The content of hydroxyproline (HYP) was detected by alkaline hydrolysis and the mRNA and protein expression of related genes in pulmonary tissues were detected by using q-PCR, ELISA, and Western blot. Our studies have shown that QLT significantly reduced the inflammatory injury, hydroxy-proline content, and collagen deposition of pulmonary tissue in BLM-induced PF mice and down-regulated the cytokine related to inflammation and fibrosis and PF expression on the mRNA and protein level in PF mice. To identify the mechanism of QLT, the Transcriptome was measured and the IL-17 signal pathway was screened out for further research. Further studies indicated that QLT reduced the mRNAs and protein levels of interleukin 17 (IL-17), c-c motif chemokine ligand 12 (CCL12), c-x-c motif chemokine ligand 5 (CXCL5), fos-like antigen 1 (FOSL1), matrix metalloproteinase-9 (MMP9), and amphiregulin (AREG), which are inflammation and fibrosis-related genes in the IL-17 signal pathway. The results indicated that the potential mechanism for QLT in the prevention of PF progression was by inhibiting inflammation resulting in the IL-17 signal pathway. Our study provides the novel scientific basis of QLT and represents new therapeutics for PF in clinical.

Establishment of fingerprint and mechanism of anti-myocardial ischemic effect of Syringa pinnatifolia

OBJECTIVE

To establish the fingerprint of Syringa pinnatifolia Hemsl. (SP), analyze the blood components of SP, and explore the possible mechanism of SP's anti-myocardial ischemia, so as to provide scientific basis for the follow-up development and research of SP and lay a foundation for its clinical application.

METHODS

The fingerprint of SP was established by UPLC-QE-MS and GC-MS. A rat Myocardial infarction (MI) was constructed by ligating the left anterior descending branch (LAD) of the rat coronary artery, and SP alcohol extract was administered to evaluate its anti-myocardial ischemic effect. We analyzed the blood components of SP, screened the active compounds, established a database of SP anti-myocardial ischemic targets, and explored the possible mechanism of SP in treating MI by bioinformatics. The rats were examined by echocardiography, serum biomarkers were determined, and pathological changes were observed by histopathological examination. TUNEL staining was performed to detect the apoptotic level of cells, and western blot and qRT-PCR were performed to detect the expression levels of Bcl-2, Bax and caspase-3 in heart tissues.

RESULTS

In the fingerprint of SP, 24 common peaks were established, and the similarity evaluation results of 10 batches of SP were all > 0.9. UPLC-QE-MS and GC-MS detected a total of 17 active ingredients in the drug-containing serum, including terpenoids, flavonoids, phenols, phenylpropanoids and phenolic acids, the most abundant of which was resveratrol. Enrichment analysis of SP targets against myocardial ischemia revealed that key candidate targets of SP were significantly enriched in multiple pathways associated with apoptosis. Resveratrol was administered to the successfully modeled rats, and the results showed that the resveratrol group significantly reduced LVEDd and LVEDs and significantly increased EF and FS in all groups compared with the model group. Resveratrol significantly reduced the levels of CK-MB and LDH in serum compared to the model group (p < 0.001). Hematoxylin-eosin (HE) staining of rat myocardial tissue showed that all lesions were reduced under microscopic observation in the resveratrol group compared with the model group. RT-PCR and western blot results showed that resveratrol group down-regulated the expression of the pro-apoptotic factor Bax, up-regulated the expression of the anti-apoptotic factor Bcl-2, and decreased the expression of Caspase-3.

CONCLUSION

The established fingerprints are accurate, reliable and reproducible, and can be used as an effective method for the quality control of the herbs. The anti-myocardial ischemia effect of SP may be that resveratrol can improve cardiac function and inhibit cardiomyocyte apoptosis to protect cardiomyocytes. The present study provides ample evidence for the clinical use of SP, suggesting that this drug has great potential in the treatment of ischemic heart disease.

An Overview of Herbal Medicines for Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung scarring condition with the histological characteristic of typical interstitial pneumonia. Injury to alveolar epithelial cells is a critical precursor in the pathogenesis of this disease. The prevalence of IPF is growing exponentially, with substantial morbidity and mortality rates increasing the burden on economic healthcare costs. A multidisciplinary approach for diagnosis is used to rule out the alternative causes of interstitial lung disease. Pirfenidone and nintedanib, two innovative antifibrotic medicines introduced in recent years, have provided therapeutic benefits to many IPF patients, and several IPF medications are in the early phases of clinical trials. However, available medications can cause unpleasant symptoms such as nausea and diarrhoea. More efforts have been made to uncover alternative treatments towards a more personalised patient-centred care and hence improve the outcomes in the IPF patients. Through a multi-level and multi-target treatment approach, herbal medicines, such as Traditional Chinese Medicine (TCM), have been identified as revolutionary medical treatment for IPF. Due to their natural properties, herbal medicines have shown to possess low adverse effects, stable therapeutic impact, and no obvious drug dependencies. Herbal medicines have also shown anti-inflammatory and anti-fibrotic effects, which make them a promising therapeutic target for IPF. A growing number of formulas, herbal components, and various forms of Chinese herbal medicine extracts are available for IPF patients in China. This review summarises the role of herbal medicines in the prevention and treatment of IPF.